Document is current
Any future updates will be listed below
-
Authors
Li, Melvin
McCullum, Chenille A.
Rolle, Louis T. A.
Ni, Qin
Ge, Zhuoxu
Sun, Sean X.
Pienta, Kenneth J.
Amend, Sarah R.
-
Funding
Funding for this research was provided by:
National Institutes of Health (R01 GM134542)
National Cancer Institute (U54CA143803)
Prostate Cancer Foundation
US Department of Defense CDMRP/PCRP 367 (W81XWH-20-10353)
Patrick C. Walsh Prostate Cancer Research Fund
- License Information
-
More Information
Article History
Received: 8 August 2025
Accepted: 21 December 2025
First Online: 6 January 2026
Competing interests
: K.J.P. is a consultant to Cue Biopharma, Inc., an equity holder in PEEL Therapeutics, and a founder and equity holder in Keystone Biopharma, Inc. S.R.A. is an equity holder in Keystone Biopharma, Inc. The companies were not involved in the design, collection, analyses or interpretation of data, writing of the manuscript, or the decision to publish the results. ML, CAM, LTAR, QN, ZG, and SXS declare no competing interests.
